Walking 10,000 steps can burn anywhere from 300 to 600 calories, says Padilla. So, “it's definitely a good benchmark or ...
Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...
STRIDE investigator Marc Bonaca, MD, MPH, University of Colorado School of Medicine, highlights how the data could provide insight into peripheral artery disease and type 2 diabetes treatment options.
Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...
The GLP-1 agonist has shown convincing benefits in yet another population, patients with peripheral arterial disease, in a ...
While the exact mechanism is unknown, the data suggest a multitude of benefits independent of large weight loss.
CHICAGO -- Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building ...
The treatment of many patients with peripheral artery disease is not optimal, and indeed is much worse than that in patients ...
Among patients with diabetes and peripheral artery disease, semaglutide 1 mg increased walking distance vs. placebo, ...